ニュース

The European Commission has awarded VIVEbiotech the Seal of Excellence for the development of Lentisoma, an innovative safe vehicle for genes that serve as medicines.

VIVEbiotech is a Company with a very wide expertise in Lentiviral vectors, having been focused on it during the last years.

The biotechnology company VIVEbiotech and the delegation of the Basque Country of the Spanish Federation of Rare Diseases (Federación Española de Enfermedades Raras, FEDER) have signed a collaboration agreement that will allow people suffering from a rare disease in the Basque Country to receive a quality, comprehensive and specialized support.

What are viral vectors? What are they used for? Juan Carlos Ramírez, the Scientific Director of VIVEbiotech, clarifies these doubts about viral vectors, the “vehicles” in which VIVEbiotech works, the ones that could be used to cure monogenic diseases in the future.

Biotechnology of the Basque Country whose protagonist is VIVEbiotech.

The Second Symposium on New Tools for Gene Editing, organized among others by VIVEbiotech, focused on the various applications of CRISPR-Cas tools, which are already being implemented in different laboratories across the country—both in basic research labs and in applied research units with a more translational approach.

BIO‑Europe, one of the most important biotechnology industry events in Europe, will be held this year in Cologne (Germany).

VIVEbiotech took part this year in the eighth edition of BioSpain 2016, the biennial event for the biotechnology sector, with its own stand in the Biobasque pavilion, dedicated to the development and consolidation of new businesses in the life sciences sector.